JCB, Volume 13, Number 1, 2006 Article Vol.13 No. 1 (2006) Biotechnology in Cuba: 20 years of scientific, social and economic progress Ernesto López Mola An analysis of the biotechnology development in Cuba for 20 years has been attempted in this paper. This paper deals with the evolution of the biotechnology sector from Article Vol.13 No. 1 (2006) Country-of-origin effect of VC investment in biotechnology companies Siah Hwee Ang Biotechnology companies can access financial and management resources through venture capitalist (VC) firms. An analysis of 1,490 VC investments shows that country-of-o Article Vol.13 No. 1 (2006) A retrospective prospective perspective on agricultural biotechnology ten years on Martina Newell McGloughlin Since the first biotech crop was commercialised in 1996, these crops have enjoyed a rapid adoption and are now grown commercially by 8.5 million farmers in 21 countries Article Vol.13 No. 1 (2006) Using intellectual property to map the organisational evolution of firms: Tracing a biotechnology company from startup to bureaucracy to a multidivisional firm Iraj Daizadeh The concomitant rise in the number of technology firms, US issued patents, and patent communications has forced researchers to investigate how such publicly known infor Article Vol.13 No. 1 (2006) When is patent infringement not patent infringement? Merck v Integra and the 'safe harbour' Karen I Boyd The Supreme Court recently ruled on the scope of the patent infringement 'safe harbour' of 35 U.S.C. §271(e)(1), which was passed by Congress in 1984 to allow generi Article Vol.13 No. 1 (2006) Media coverage and biotechnology IPOs: Some Australian evidence Paul Jens This paper analyses Australian biotechnology initial public offerings and the role of media coverage during the issue period in explaining capital raising, sentiment an Article Vol.13 No. 1 (2006) Increased uptake of biologics in historically small molecule blockbuster-dominated therapeutic areas Duncan A N Emerton The two leading therapeutic areas for biologic products, in terms of current sales and pipeline focus, are oncology and AIID (arthritis, immune and inflammatory disorde Legal and Regulatory Updates Vol.13 No. 1 (2006) Legal and regulatory update John Wilkinson  Â
